A new study that compared the newer drug, letrozole, to the widely used tamoxifen found that the former was more effective. The study confirmed that survival rates for postmenopausal women, who are suffering from breast cancer and have undergone surgery, taking letrozole (Femara) are higher than that taking tamoxifen. Both letrozole and tamoxifen have been used to prevent recurrence of breast cancer in postmenopausal women with hormone receptor-positive cancer.

The American Society of Clinical Oncology (ASCO) is set to honor individuals who have consistently worked towards making tremendous advancements in the field of cancer. Among those being rewarded for their lifetime commitment to improving the lives of people living with cancer are Dr. Jordan, the first scientist to demonstrate tamoxifen’s effectiveness in the prevention of breast cancer, and Mary-Claire King, who was the first to provide proof of the genetic inheritance of breast cancer.